Found: 166
Select item for more details and to access through your institution.
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01140-5
- By:
- Publication type:
- Article
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01120-9
- By:
- Publication type:
- Article
Bispecific antibodies in the treatment of multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01139-y
- By:
- Publication type:
- Article
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01137-0
- By:
- Publication type:
- Article
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01135-2
- By:
- Publication type:
- Article
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01133-4
- By:
- Publication type:
- Article
Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms.
- Published in:
- 2024
- By:
- Publication type:
- Letter
B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01123-6
- By:
- Publication type:
- Article
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01122-7
- By:
- Publication type:
- Article
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01129-0
- By:
- Publication type:
- Article
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01126-3
- By:
- Publication type:
- Article
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01124-5
- By:
- Publication type:
- Article
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Disparities in time to treatment with oral antimyeloma medications.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01128-1
- By:
- Publication type:
- Article
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01116-5
- By:
- Publication type:
- Article
Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01121-8
- By:
- Publication type:
- Article
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01117-4
- By:
- Publication type:
- Article
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
- Published in:
- 2024
- By:
- Publication type:
- Letter
A roadmap towards improving outcomes in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01115-6
- By:
- Publication type:
- Article
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01109-4
- By:
- Publication type:
- Article
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Identification of genetic subtypes in follicular lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01111-w
- By:
- Publication type:
- Article
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01102-x
- By:
- Publication type:
- Article
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01105-8
- By:
- Publication type:
- Article
IgG replacement in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01107-6
- By:
- Publication type:
- Article
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01081-z
- By:
- Publication type:
- Article
Correction: Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Racial disparities in multiple myeloma and access to stem cell transplantation.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01096-6
- By:
- Publication type:
- Article
Long term responders in frontline multiple myeloma—exception vs expectation of the modern era.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01062-2
- By:
- Publication type:
- Article
Using Mendelian Randomisation to search for modifiable risk factors influencing the development of clonal haematopoiesis.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Prevalence and distribution of M-proteins in the oncologic population affected by solid tumor.
- Published in:
- 2024
- By:
- Publication type:
- Letter